The short version
- Federal and state authorities are asking a federal judge to hold Martin Shkreli in civil contempt for allegedly violating a lifetime ban on participating in the pharmaceutical industry.
- The complaint details dozens of stock trades, public livestreams discussing biotech investments, and organized campaigns to short pharmaceutical companies based on clinical trial predictions.
- Prosecutors are seeking sanctions that include full financial disclosure, divestment of holdings, monetary fines equal to illicit profits, and potential incarceration for future non-compliance.
Federal regulators and a coalition of seven state attorneys general have moved to hold Martin Shkreli in civil contempt, alleging that the former pharmaceutical executive has systematically violated a lifetime ban on participating in the drug industry. The motion, filed in federal court in New York City, asserts that Shkreli has engaged in prohibited activities since his release from prison in May 2022, directly contravening the conditions set by the judiciary following his conviction for securities fraud.
The core of the legal challenge centers on Shkreli’s alleged involvement in trading and influencing business decisions within the pharmaceutical sector. According to the filing, he has traded stocks in at least sixty different pharmaceutical companies. The restrictions placed upon him explicitly forbid any direct or indirect participation in the industry, which includes owning stakes in relevant firms or exerting influence over their operational strategies. Authorities contend that his actions since 2022 represent a clear breach of these judicial mandates.
The complaint highlights Shkreli’s use of digital platforms to publicize his activities and engage with an audience interested in biotech investments. Through livestreams on YouTube, X, and Reddit, he reportedly discussed his trading strategies openly. In one instance cited by the Federal Trade Commission, he told viewers he was demonstrating how to trade and invest in the biotechnology sector. Another broadcast featured him describing a strategy he called a magic trick, claiming that regardless of his specific trades, he could consistently identify biotech stocks with high potential for rapid gains.
Beyond individual trading, regulators allege that Shkreli used these online broadcasts to coordinate public campaigns aimed at shorting pharmaceutical stocks. These efforts were reportedly based on predictions that certain companies would fail in their clinical trials. The FTC characterizes these actions as brazen violations of the court order, arguing that they demonstrate a pattern of behavior intended to circumvent the restrictions placed on his professional activities within the healthcare sector.
The enforcement action seeks significant sanctions designed to address both past violations and future compliance. The filing requests a complete accounting of all stock trades involving pharmaceutical companies, as well as the divestment of any current ownership interests in such firms. Additionally, authorities are asking for monetary fines equivalent to the profits Shkreli allegedly generated through his contemptuous conduct. The motion also calls for clear, escalating consequences for any future infractions, which could include additional financial penalties and further incarceration.
This legal escalation stems from a 2022 ruling that found Shkreli responsible for an illegal anticompetitive scheme involving the drug Daraprim. That case involved raising the price of the medication, used to treat malaria, certain cancers, and toxoplasmosis, by more than 5,000 percent. The price hike moved from $17.50 to $750 per tablet. A US court fined him $64.6 million at that time, describing his conduct as egregious, deliberate, repetitive, long-running, and ultimately dangerous.
Daniel Guarnera, director of the FTC’s competition bureau, emphasized the importance of adhering to judicial orders in a statement accompanying the filing. He noted that defendants must fulfill their obligations when a court issues an order, adding that this action serves as notice that the agency will not hesitate to enforce violations. The stance reflects a broader regulatory effort to maintain the integrity of court-imposed restrictions on individuals with histories of market manipulation.
New York Attorney General Letitia James echoed this sentiment, stating that a court-ordered lifetime ban is not a suggestion. She criticized Shkreli for livestreaming his pharmaceutical trades for public consumption, arguing that such behavior violates the law. James asserted that his market manipulation and monopolistic tactics pose risks to both investors and the general public, justifying the return to court to halt what she described as illegal behavior.
Shkreli was originally sentenced to seven years in prison in 2018 after being found guilty of two counts of securities fraud and one count of conspiracy. His case became a prominent symbol of corporate greed during his incarceration. He was released early in May 2022, subject to the strict conditions that are now at the center of this new legal dispute. The Guardian has reached out to Shkreli for comment regarding the allegations.
The outcome of this contempt proceeding could set a significant precedent for how courts enforce lifetime bans on industry participation. If the judge rules in favor of the FTC and the states, Shkreli could face substantial financial penalties and potential return to prison. Conversely, if he successfully defends his actions as compliant with the letter of the law, it may highlight ambiguities in how digital engagement and stock trading are defined under such restrictions.
Sources behind this briefing
Go to the original reporting
- The Guardian World↗FTC and seven states seek contempt ruling against Shkreli over pharma ban
